Search
Adlinacogene civaparvovec
go.drugbank.com/drugs/DB16788InvestigationalIt uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX.
Orludodstat
go.drugbank.com/drugs/DB21498InvestigationalOrludodstat is under investigation in clinical trial NCT03404726 (A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies).
Velufenacin
go.drugbank.com/drugs/DB21473InvestigationalVelufenacin is under investigation in clinical trial NCT05282069 (A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder).
2-hydroxy-7-methoxy-5-methyl-naphthalene-1-carboxylic acid meso-2,5-dihydroxy-cyclopent-3-enyl ester
go.drugbank.com/drugs/DB08261ExperimentalThis compound belongs to the naphthalenecarboxylic acids and derivatives. These are compounds containing a napthalene moiety with a ring carbon which bears a carboxylic acid group or a derivative.
GSK-945237
go.drugbank.com/drugs/DB15345InvestigationalGSK-945237 is under investigation in clinical trial NCT01039610 (A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose … and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.).
Desmethylprodine
go.drugbank.com/drugs/DB01478ExperimentalIllicitIt is known to be a designer drug, synthesized in 1977, for the purpose of recreational use. Illicit manufacturing has occurred.
VSF-173
go.drugbank.com/drugs/DB05753InvestigationalStudy shows that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness.
Merbromin
go.drugbank.com/drugs/DB13392Investigationalan organomercuric disodium salt compound and a fluorescein that is available in many countries, except Switzerland, France, Germany, and the United States where the drug was withdrawn from market due to
Bexotegrast
go.drugbank.com/drugs/DB16515InvestigationalPLN-74809 is a small-molecule that dually inhibits both α<sub>v</sub>β<sub>6</sub> and α<sub>v</sub>β<sub>1</sub> to treat both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC … The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical